Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective
Y Huang, H Sun, H Yu, S Li, Q Zheng… - Antibody …, 2020 - academic.oup.com
The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …
The development of neutralizing antibodies against SARS-CoV-2 and their common features
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide
severe coronavirus disease 2019 (COVID-19) pandemic since December 2019. There is a …
severe coronavirus disease 2019 (COVID-19) pandemic since December 2019. There is a …
SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment
D Li, GD Sempowski, KO Saunders… - Annual review of …, 2022 - annualreviews.org
Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
[HTML][HTML] Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2
G Zhou, Q Zhao - International Journal of Biological Sciences, 2020 - ncbi.nlm.nih.gov
A newly identified novel coronavirus (SARS-CoV-2) is causing pneumonia-associated
respiratory syndrome across the world. Epidemiology, genomics, and pathogenesis of the …
respiratory syndrome across the world. Epidemiology, genomics, and pathogenesis of the …
[HTML][HTML] Neutralizing monoclonal antibodies for treatment of COVID-19
PC Taylor, AC Adams, MM Hufford… - Nature Reviews …, 2021 - nature.com
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
Antibody therapies for the treatment of COVID-19
The outbreak of COVID-19, the disease caused by infection of the coronavirus SARS-CoV-2
that began in December 2019 in Wuhan, China, has caused more than 2 990 559 confirmed …
that began in December 2019 in Wuhan, China, has caused more than 2 990 559 confirmed …
Structural basis of SARS-CoV-2 and SARS-CoV antibody interactions
E Gavor, YK Choong, SY Er, H Sivaraman… - Trends in …, 2020 - cell.com
The 2019 coronavirus pandemic remains a major public health concern. Neutralizing
antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute …
antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute …
SARS‐CoV‐2 neutralising antibody therapies: Recent advances and future challenges
The COVID‐19 pandemic represents an unparalleled global public health crisis. Despite
concerted research endeavours, the repertoire of effective treatment options remains limited …
concerted research endeavours, the repertoire of effective treatment options remains limited …
Antibody-mediated neutralization of SARS-CoV-2
Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …
Broadly neutralizing antibodies to SARS-CoV-2 provide novel insights into the neutralization of variants and other human coronaviruses
P Bajpai, V Singh, A Chandele… - Frontiers in Cellular and …, 2022 - frontiersin.org
Seven coronaviruses are known to cause infection/disease in humans. Of these, human
coronavirus (HCoV)-229E and HCoV-NL63 are alphacoronaviruses (α-CoVs), whereas …
coronavirus (HCoV)-229E and HCoV-NL63 are alphacoronaviruses (α-CoVs), whereas …